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Summary  Respiratory  syncytial  virus  (RSV)  is  a  leading  cause  of  acute  respiratory
infection  during  early  childhood  and  is  associated  with  a  great  burden  on  patients,
parents,  and  society.  While  no  treatment  is  yet  available,  results  from  recent  phase
2  clinical  trials  of  cell-entry  inhibitors  and  RSV  vaccines  are  promising.  To  prepare
for  introduction  of  these  novel  therapeutics,  good  understanding  of  its  molecular
epidemiology  and  continuous  RSV  surveillance  data  are  necessary.  This  paper  pro-
vides  an  overview  of  RSV  prevalence  and  genotype  distribution  in  Iran  from  1996Iran
to  2013.  This  meta-analysis  includes  21  published  studies.  In  total,  775  (18.7%)  of
4140  respiratory  specimens  were  positive  for  RSV  infection.  The  male-female  ratio
of  RSV-positive  patients  was  1.5:1.  Signiﬁcant  peaks  of  RSV  infection  were  detected
during  the  cold  season  (November—March).  RSV  infection  was  mainly  observed  in
patients  <2  years  of  age.  Phylogenetic  studies  showed  that  genotypes  GA1,  GA2,  GA5,
and  BA  co-circulated  in  Iran  in  2007—2013.  This  review  highlights  the  necessity  of
Abbreviations: RSV, respiratory syncytial virus; Flu, inﬂuenza; PIV, parainﬂuenza; AdV, adenovirus; hBoV, human bocavirus; hMPV,
uman metapneumovirus.
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introducing  standard  molecular  surveillance  programs  to  inform  the  epidemiological,
clinical,  and  pathological  characteristics  of  various  RSV  genotypes.  Improved  under-
standing  of  the  molecular  epidemiology  will  be  useful  for  development  of  novel  RSV
therapeutics.
©  2015  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
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Introduction
Viral  respiratory  infections  pose  considerable
health difﬁculties  for  people  of  various  ages  world-
wide  [1].  Respiratory  syncytial  virus  (RSV)  infection
is a  leading  cause  of  hospitalization  in  infants  less
than 1  year  old  and  an  important  cause  of  clin-
ical referral  among  children  less  than  5  years  of
age in  developed  countries  [2,3];  it  is  also  consid-
ered a  signiﬁcant  pathogen  in  adults  [1].  The  major
viral respiratory  pathogens  include  RSV,  inﬂuenza
(Flu) types  A  and  B,  parainﬂuenza  (PIV)  types  1—4,
adenovirus  (AdV),  rhinovirus,  enterovirus,  human
bocavirus  (hBoV)  and  human  metapneumovirus
(hMPV),  all  of  which  present  with  similar  clinical
features in  infected  patients  [4]. RSV  is a  pneu-
movirus belonging  to  the  Paramyxoviridae  family.
This negative-sense  single-stranded  RNA  virus  is
characterized  by  large  syncytia  in  single-layer
cells [5].  Epidemiological  studies  have  reported
that RSV  has  a  seasonal  distribution  pattern,  with
peak prevalence  between  early  November  and  late
infants.  Recent  studies  describe  the  increased  risk
of wheezing  and  asthma  after  RSV  bronchiolitis  [6].
Increased risk  of  severe  RSV  infection  has
been reported  among  premature  infants;  those
with bronchopulmonary  dysplasia,  airway  congen-
ital abnormalities,  cystic  ﬁbrosis,  atopy,  and  Down
syndrome;  and  preterm  children  with  chronic
lung disease  [1,7]. Considering  the  critical  role
of the  immune  system,  particularly  neutrophils,
in RSV  infection,  research  has  focused  on  its
immunopathogenesis  in  order  to  characterize  the
molecular mechanisms  of  virus  replication  to  design
more efﬁcient  drugs  and  vaccines  [8—10].
Both classical  and  molecular  diagnosis  methods
are currently  used  for  RSV  detection;  however,
molecular assays,  especially  reverse  transcription
PCR (RT-PCR),  offer  increased  sensitivity,  speci-
ﬁcity, and  rapidity  [5]. The  RSV  genome  encodes
11 proteins,  including  two  nonstructural  proteins.
The nucleotide  sequence  of  the  variable  regions
within the  G  glycoprotein  are  mainly  used  to
determine RSV  genotype  and  for  epidemiologicalJanuary  in  most  communities  [5]. RSV  can  be
involved in  upper  and  lower  respiratory  tract  infec-
tions and  progress  to  bronchiolitis  and  pneumonia  in
p
c
purposes [11]. Based  on  its  reaction  with  mono-
lonal antibodies  against  glycoprotein  G  and  fusion
rotein  F,  RSV  has  two  main  genetic  subtypes,
P ulat
A
(
t
A
t
r
l
o
t
[
t
t
c
i
d
t
f
i
a
[
m
p
p
t
l
i
t
d
M
W
i
d
I
e
i
a
O
e
f
t
s
R
(
a
e
i
r
s
o
t
r
1
r
c
c
q
i
2
m
t
1
M
t
R
P
T
l
w
a
c
t
f
i
o
7
f
a
T
i
s
o
a
h
f
p
b
c
i
r
R
T
w
(
i
a
t
w
i
(
lrevalence  of  human  respiratory  syncytial  virus  circ
 and  B.  There  are  11  genotypes  in  subtype  A
GA1-7,  SAA1,  ON1,  and  NA1-2)  and  20  in  sub-
ype B  (GB1-4,  BA1-10,  SAB1-4,  and  URU1-2)  [12].
lthough these  subtypes  can  co-circulate,  sub-
ype A  tends  to  be  predominant,  which  might
eﬂect time  or  geographical  factors;  virus  circu-
ation  and  evolution  can  be  affected  by  several
ther factors  including  virus  infectivity  and  spon-
aneous  mutations  as  well  as  host  group  immunity
13,14].  Gender-related  susceptibility  to  RSV  infec-
ion, with  male  children  reportedly  more  at  risk
han females,  remains  controversial  [12];  however,
omparatively  higher  percentages  of  respiratory
nfections are  reported  in  women,  which  might  be
ue to  increased  exposure  to  airborne  infections
hrough frequent  contact  with  children  and  elderly
amily  members.
Since RSV  plays  a  critical  role  in  respiratory
nfection  epidemics  and  might  be  associated  with
sthma  occurrence  and  development  in  later  life
15],  RSV  detection  is  of  particular  interest.  The
ulti-seasonal  climate  of  Iran  as  well  as  its  highly
opulated  regions  and  diverse  ethnic  populations
rompted us  to  analyze  published  studies  in  order
o provide  valuable  information  about  the  preva-
ence of  this  virus  in  this  population.  Regional  data
s crucial  for  predicting  the  impact  of  RSV  infec-
ion on  developing  asthma  and  for  improving  virus
iagnosis.
ethods
e  reviewed  all  published  studies  about  RSV  in  Iran
dentiﬁed  by  searching  PubMed,  Medline,  national
atabases  (Scientiﬁc  Information  Database  [SID],
randoc, Iranmedex,  MagIran),  and  related  refer-
nces from  relevant  articles.  Search  key  words
ncluded ‘‘RSV’’,  ‘‘respiratory  syncytial  virus,’’
nd ‘‘Iran’’  in  both  English  and  Persian  language.
verlapping, unrelated,  and  unreliable  data  were
xcluded.  The  following  details  were  extracted
rom each  source:  journal  name,  year  of  publica-
ion, ﬁrst  author,  season,  number  of  cases,  sample
ize, age  range  (if  available),  city,  number  of
SV-positive  individuals,  patient  clinical  features
if available),  methods  (direct  immunoﬂuorescence
ssay [IFA],  indirect  IFA,  RT-PCR,  real-time  PCR,
nzyme-linked  immunosorbent  assay  [ELISA],  or
mmunochromatography),  sample  type  (nasopha-
yngeal  swabs,  nasopharyngeal  aspirate,  or  throat
wabs),  hospitalization  history  (if  available),  and
ther respiratory  viruses.  Ten  papers  were  iden-
iﬁed  by  ‘‘snowballing’’  (pursuing  references  of
eferences  and  electronic  citation  tracking),  and
7 papers  by  database  browsing.  A  total  of  21
A
a
i
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eliable  published  studies  were  considered  in  the
urrent review  (Table  1).  The  data  from  these  21
ross-sectional  studies  were  both  quantitative  and
ualitative. A  total  of  4140  respiratory  specimens
nvestigated in  21  studies  in  Iran  from  1996  to
013 were  included  in  our  survey.  These  cases  were
ainly acute  upper  and  lower  respiratory  infec-
ions.  The  age  distribution  of  patients  ranged  from
 month  to  60  years.  Data  were  entered  into  a
icrosoft  Excel  version  14  spreadsheet  and  descrip-
ive  analyses  conducted.
esult
revalence of RSV circulating in Iran
he  age  distribution  of  the  4140  cases  was  as  fol-
ows: in  14  of  21  studies,  respiratory  specimens
ere collected  from  children  less  than  5  years  of
ge; in  5 out  of  21  studies,  respiratory  samples  from
hildren less  than  15  years  of  age  were  included  in
he survey;  the  remaining  studies  collected  samples
rom  patients  5—60  years  of  age.  Thus,  the  major-
ty of  samples  were  from  children  less  than  5  years
f age.  Based  on  data  analysis  of  21  studies  in  Iran,
75 of  4140,  respiratory  specimens  were  positive
or RSV.  The  average  percentage  of  RSV  positivity  in
ll samples  was  18.7%  during  1996—2013  (Table  1).
his pattern  was  consistent  with  estimated  RSV
nfection  prevalence  of  reported  in  epidemiologic
tudies in  other  countries.  Molecular  epidemiology
f circulating  RSV  detected  in  the  Philippines  [14]
nd  rural  Thailand  [16]  revealed  that  19%  of  cases
ospitalized  with  severe  pneumonia  were  positive
or RSV.  In  the  current  study,  the  percentage  of  RSV
ositivity  among  respiratory  samples  from  neigh-
oring  countries  such  as  Pakistan  was  17.8%  among
hildren  hospitalized  for  severe  pneumonia  dur-
ng 2010—2011  [17]. A  study  conducted  in  Kenya
eported 16.5%  of  severe  pneumonia  cases  were
SV-associated,  consistent  with  our  ﬁndings  [18].
he percentage  of  RSV  positivity  in  Iran,  however,
as higher  than  in  countries  such  as  Cameroon
5.7%) [19]  and  Kenya  (12.5%)  [20], but  lower  than
n recent  reports  from  Latvia  (33%  to  57%)  [21]
nd  Turkey  (37.9%)  [22]. The  rate  of  RSV  detec-
ion varied  over  time  in  studies  conducted  in  Iran,
ith low  and  high  rates  of  5.7%  and  45.8%  reported
n 2007  and  between  2009  and  2011,  respectively
Table  1).  Despite  the  use  of  sensitive  techniques
ike RT-PCR,  lower  detection  rates  were  reported  in
rak and  Ahwaz  during  2008—2009  (Table  1);  there
re several  possible  reasons  for  this  observation,
ncluding hospitalization  history,  since  all  samples
n the  Arak  study  were  from  outpatient  cases.  The
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Table  1  RSV  positivity  rate  from  21  studies  of  acute  respiratory  infection  in  Iran,  n  (%).
Location  Year  Age  range  No.  of
cases
RSV  positive
rate
Type of
sampled
Methode Clinical  features  Hospitalization  Ref.
Tehran  Oct  1996  —Mar
1998
<14  yr  268  33  (12.3%)  NPS  Cell  culture
and  DIF
Cough,  bronchiolitis,  fever  Outpatient  [40]
Tehran  Nov—Mar  1998  <5  yr  365  70  (19.2%)  NPA  Cell  culture
and  DIF
Cough,  coryza,  pneumonia,
bronchiolitis
14  (20%)  [41]
Tehran  Jan—May  1999  <5  yr  145  56  (38.6%)  NPA  DIF  Bronchiolitis  36  (37.9%)  [42]
Tehran Mar—Nov  2001 2  m—14  yr 83  20  (23%) NPS  IIF  Cough,  fever,  rhinorrhea,
wheezing
20  (100%) [43]
Mazandaran Oct  2001—May
2002,  Jun  to  Nov
2003
1  m—5  yr 202  26  (12.9%) NPS  IIF  Fever  recurrent  wheezing 26  (100%) [44]
Tabriz 2002  1  m—5  yr 252  62  (24.6%)  Not  stated  DIF  Pneumonia,  bronchiolitis,
wheezing,  cyanosis,
conjunctivitis
Not  stated  [45]
Rasht Nov  2003—Mar
2004
2  m  —5  yr  261  39  (15%)  NPA,  NPS  RT-PCR  cough,  fever,  tachypnea  122  (46.7%)  [46]
Tehran  2005—2006  5—60  yr  212  34  (16%)  NPS  DIF  Body  pain,  fever,  cough,
malaise
Not  stated  [47]
Kerman  2006  <2  yr  168  63  (37.5%)  NPS  RT-PCR  Bronchiolitis  Not  stated  [48]
Tehran  2007  3  m—15  yr  160  9  (5.7%)  NPS  IMC  Fever,  cough,  vomiting,
diarrhea,  sore  throat,
abdominal  pain,
conjunctivitis
Not  stated  [49]
Tehran  Oct  2007  —Sep
2008
<17  yr  50  7  (14%)  NPA,  NPS  RT-PCR  and
Rt-PCR
Fever,  cough,  Dyspnea,  Rales,
Wheezing
Not  stated  [50]
7  citiesa 2007—2008  <5  yr  72  14  (19.4%)  TS  RT-PCR  Wheezing,  fever,  caught  10  (71.4%)  [27]
Shahre-kord  2007—2008  2  m—5  yr  300  26  (8.6%)  Serum  ELISA  pneumonia,  pharyngitis,
bronchiolitis,  croup
26  (100%)  [51]
Arak  Nov-2008  2  m—10  yr  300  18  (6%)  NPS  RT-PCR  Coryza,  cough,  sneezing,  sore
throat,  headache,  fever,
conjunctivitis,  abdominal
pain,  hoarseness
Outpatient  [52]
Tehran Mar  2008—May
2009
<6  yr 202  34  (16.8%) TS  RT-PCR  acute  respiratory  symptoms  34  (100%)  [24]
Ahwaz  Oct  2008  —Apr
2009
<5  yr 100  9  (9%)  NPS  RT-PCR  Bronchiolitis,  cough,  coryza,
fever,  chest  wall  retraction,
wheezing,  cyanosis
9 (100%)  [53]
13  citiesb 2009  <5  yr  107  24  (22.4%)  TS  RT-PCR  Wheezing,  cough,  fever  24  (100%)  [28]
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cigure  1  Distribution  of  respiratory  syncytial  virus  infec-
ions  in  Iran  between  1996  and  2013,  according  to  gender.
mall  sample  size  in  the  Ahwaz  study  also  might
ave inﬂuenced  the  ﬁndings.  High-quality  samples
re required  for  good  virus  detection;  lower  sample
uality in  these  cities  might  also  have  contributed
o the  reduced  detection  rate  of  RSV.  High  detec-
ion rates  have  been  reported  in  a  number  of  studies
rom Tehran  (38.6%,  40.2%,  and  45.8%)  and  Ker-
an (37.5%)  (Table  1),  which  were  higher  than
he 12.6—24.6%  reported  in  other  places  (Table  1).
SV infections  were  more  frequently  observed  in
ospitalized  patients  (14  studies).  Sixteen  studies
peciﬁed  the  number  of  inpatients  and  outpatients,
nd more  than  63%  of  RSV-positive  cases  were  hospi-
alized.  Our  results  using  available  studies  indicate
hat most  RSV-positive  outpatients  were  less  than
 years  old.  RSV  infections  were  mainly  observed
efore 2  years  of  age  [23]. No  lethal  RSV  infections
ere reported  in  Iran  from  1996  to  2013.
SV gender differences
he  male-female  ratio  of  RSV-positive  patients  in
ur analysis  was  1.5:1,  indicating  a higher  occur-
ence of  RSV  infections  in  male  patients  (Fig.  1).
owever,  higher  percentage  of  men  enrolled  in
he surveys  might  contribute  to  this  ﬁnding,  since
tudies  from  other  countries  have  not  reported  sig-
iﬁcant gender  differences  [23].
egional differences in RSV
ur  analysis  revealed  that  available  data  on  RSV-
elated reports  evaluated  19  of  31  provinces  in
he center,  northern,  northwestern,  and  southwest-
rn  parts  of  Iran.  No  data  were  reported  from  the
estern,  eastern,  northeastern,  or  southeastern
egions of  Iran,  except  for  Hormozgan  and  Kerman
rovinces,  which  are  located  in  the  south  (Fig.  2).
he reasons  for  variable  geographic  RSV  preva-
ence cannot  be  concluded  from  available  data,  but
ne possible  explanation  might  include  the  local
limates  in  these  provinces  [21]. It  is apparent
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DFigure  2  Geographic  distribution  of  respiratory  syncytial
distribution  of  respiratory  syncytial  virus  cases  related  to
that  additional  data  from  all  provinces  in  Iran  are
required  to  determine  the  exact  prevalence  pat-
tern and  frequency  of  RSV  genotypes  nationwide.
Signiﬁcant peaks  of  RSV  prevalence  were  detected
in the  cold  seasons  (November—March).  This  ﬁnd-
ing underlined  the  seasonal  characteristics  of  RSV
infections  in  Iran,  which  is  consistent  with  patterns
of age  and  seasonal  RSV  prevalence  reported  in
other studies  [16,18].
RSV co-infection
Co-infection  of  RSV  with  other  respiratory  viruses
is common,  which  may  increase  the  risk  of  severe
acute  respiratory  infections  associated  with  respi-
ratory distress,  such  as  bronchiolitis,  compared  to
single RSV  infections  [4]. RSV  co-infection  was  only
reported  in  two  studies  in  our  survey,  consisting
of 9/43(20.9%)  [24]  and  11/44  (20.5%)  cases  [25].
According to  Malekshahi  et  al.  [24],  the  rate  of
RSV co-infection  with  hMPV,  PIV-1,  AdV,  and  Flu
was 1/44  (2.32%),  4/44  (9.3%),  3/44  (6.97%),  and
1/44 (2.32%),  respectively.  However,  Chavoshzadeh
et al.  [25]  have  shown  that  the  RSV  co-infection  rate
with hMPV  and  rhinoviruses  is  5/44  (11.36%)  and
4/44 (9.1%),  respectively.  No  relationship  between
L
i
p
ns  cases  between  1996  and  2013  (small  stars)  and  genotype
graphical  location  in  Iran,  2009—2013  (small  triangles).
SV  co-infections  and  increased  severity  of  virus-
ependent  diseases  was  found  in  either  study.
ccording to  the  small  number  of  reports  on  this
opic,  the  proportion  of  co-infections  requires
eriﬁcation in  future  studies  and  evaluations  to
etermine  if  these  ﬁndings  are  incidental  or  have
linical signiﬁcance.  Mixed  infections  have  been
eported  in  many  studies;  however,  the  rates  of
SV co-infection  with  other  viruses  have  varied  sub-
tantially from  4%  to  53%  [26]. Hospitalized  children
ad higher  rates  of  co-infections  [26], and  RSV  co-
nfection  with  hMPV  was  reportedly  associated  with
isease severity  such  that  mechanical  ventilation
as required  [17].
In six  of  21  studies,  other  respiratory  viruses
ncluding AdV,  PIV  types  1—3,  hBoV,  Flu  type  A
nd B,  and  hMPV  were  also  detected  independently
rom RSV  infections;  AdV  (14.22%)  and  PIV  type  3
10.15%) were  most  commonly  observed  (Table  2).
istribution of RSV genotypesimited  information  exists  regarding  RSV  genotypes
n Iran.  Among  the  current  studies,  only  three
rovided information  about  RSV  genotypes  using
ested  RT-PCR  and  partial  G  protein  sequencing.
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Table  2  Detection  rates  of  RSV,  adenovirus,  inﬂuenza  virus,  parainﬂuenza  virus,  boca  virus  and  metapneumovirus
in  children  with  acute  respiratory  infection  in  21  studies  in  Iran  between  1996  and  2013.
Viral  agent  No.  of  samples
tested
Positivity
rat,  n  (%),
No.  of
studies
Year  Ref.
Respiratory  syncytial
Virus
4140  775  (18.7%)  21  1996—2013  [13,24,25,27,28,40—55]
Adenovirus  1125  160  (14.22%) 5  2001—2004,  2007—2009  [40,45—47,52]
Parainﬂuenza  virus
type  3
404  41  (10.15%) 2  2001—2002,  2009—2010 [45,52]
Human  bocavirus  261  21  (8.02%)  1  2003—2004  [46]
Parainﬂuenza  virus
type  2
202  13  (6.43%)  1  2001—2002  [52]
Inﬂuenza  virus  type  A  1125  59  (5.24%)  5  2001—2004,  2007—2009  [40,45—47,52]
Parainﬂuenza  virus
type  1
904  42  (4.65%)  4  2001—2002,  2007—2009  [28,45,47,52,28]
Inﬂuenza  virus  type  B  404  8  (1.98%)  2  2001—2002,  2008—2009  [45,52]
Human
metapneumovirus
202  1  (0.5%)  1  2008—2009  [45]
We just considered the studies that have detected RSV as well as other respiratory viruses. We  have excluded those studies that
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pdetected other respiratory viruses except RSV.
he  ﬁrst  report,  from  Faghiloo  et  al.  (2011),
eported a  prevalence  of  GA1,  GA2,  and  GA5  during
he winter  in  2007—2008  [27],  and  GA1,  GA2,  and
A during  the  same  season  in  2009  [28]. In  2014,
he same  group  identiﬁed  GA1,  GA2,  and  BA  geno-
ypes from  2009  to  2013  [13]. The  circulating  RSV
enotypes  in  Iran  ﬂuctuated  in  2007—2013.  Accord-
ngly,  GA2  was  predominant  during  2007—2008
nd reappeared  during  2010—2012.  Both  GA1  and
A2 circulated  in  2011—2013;  however,  GA1  was
redominant.  GA5  was  only  detected  in  2008.  Geno-
ype BA  with  a  60-nucleotide  duplication  in  the
-terminal  region  of  the  G  protein  was  detected
n 2009  and  2013.  These  ﬁndings  were  consistent
ith other  studies  reporting  shifts  in  the  predomi-
ant genotype  between  seasons  [29].  The  interplay
f pre-existing  immunity  in  the  community  and  the
enetic and  antigenic  properties  of  the  RSV  virus  to
vade the  immune  response  may  explain  changes
n genotype  dominance  over  time  [30].  The  pre-
ominance  of  RSV-A  viruses  has  been  attributed
o increased  variability  among  RSV-A  strains  [30].
ased on  the  fact  that  the  dominant  strains  shift
early,  evasion  of  immunity  induced  by  previous
trains may  be  a  mechanism  for  re-infection  [31].
eographical differences in RSV genotypes
he  geographical  distribution  of  RSV  genotypes
n Iran  also  varied:  genotype  GA2  was  predom-
nant in  the  south;  GA1,  GA2  and  BA  in  the
enter; and  GA1  in  the  north  (Fig.  2).  Monitor-
ng circulating  RSV  strains  in  different  geographical
egions is  essential,  particularly  in  the  western,
r
a
A
Mastern,  northwestern,  and  southeastern  parts  of
ran, where  available  data  is  lacking.  The  con-
inuous circulation  of  genotype  GA2  emphasizes
he stability  of  this  subtype;  it  has  become  an
pidemic in  Europe,  Asia  and  Africa  [30,32,33].
enotypes  GA2  and  BA  are  also  the  most  common
SV genotypes  worldwide  [30,32,34].  Recent  data
rom Israel  indicated  that  the  majority  of  RSV-A
iruses  detected  during  2008—2012  was  GA2  [32].
hese data  also  suggest  that  GA2  has  been  the
redominant RSV-A  genotype  circulating  in  the  Mid-
le East  between  2006  and  2012  [32]. However
onﬂicting data  exist  on  whether  RSV  evolution  is
emporally  or  geographically  related  [30,32].
As indicated  in  Fig.  2,  RSV  virus  subgroups  A
GA1, GA2,  and  GA5)  and  B  (BA)  co-circulate  in
he same  area  with  various  patterns  of  predom-
nance during  epidemic  periods.  Recent  studies
emonstrating the  predominance  of  genotype  BA  at
east in  subtype  B  may  suggest  a selective  advan-
age for  this  genotype;  however,  the  mechanism
as not  yet  been  deﬁned  [35]. Genetic  changes
n the  BA  genotype  have  been  proposed  to  confer
 neutralization-resistance  phenotype  that  allows
hese strains  to  escape  previous  host  immunity  and
rovide an  opportunity  for  increased  transmissi-
ility in  susceptible  populations  [35].  An  annual
hift of  dominant  strains  may  explain  frequent  rein-
ections due  to  evasion  of  immunity  induced  by
revious  strains  [21]. Several  attempts  to  clarify  the
elationship  between  clinical  severity  of  infection
nd RSV  subgroups  have  postulated  that  subgroup
 is  associated  with  more  severe  disease  [34,36].
artinello et  al.  [36]  reported  that  genotype  GA3
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aFigure  3  Overview  of  methods  used  in  studies  included  i
polymerase  chain  reaction  (RT-PCR),  enzyme-linked  imm
might  be  associated  with  more  severe  disease.  They
claimed  that  amino  acid  variations  in  the  third  C-
terminal hypervariable  region  of  the  RSV  G  gene
might  be  responsible  for  the  severity  of  RSV  infec-
tions,  such  as  bronchiolitis  [34,36].  However,  some
reports have  concluded  that  the  severity  of  RSV-
related  disease  was  not  related  to  subgroups  or
genotypes  but  was  instead  associated  with  viral
load during  primary  RSV  infection  [34].  It  is  not
known to  what  extent  these  inconsistencies  might
be attributed  to  differences  in  the  deﬁnitions  of
disease severity,  RSV  subgroup  distribution,  study
design, or  study  populations  [5].
Discussion
RSV  is  responsible  for  approximately  3.4  million
hospitalizations associated  with  lower  respiratory
tract infections  and  almost  200,000  deaths  among
children  less  than  5  years  of  age  [37].  Of  these
deaths, 99%  occur  in  developing  countries  [37].
The current  review  of  21  published  studies  from
various geographical  regions  in  Iran  allowed  us
to estimate  the  percentage  of  respiratory  tract
infections  caused  by  RSV  infection  as  well  as  the
distribution  of  RSV  genotypes  in  Iran.  Our  analy-
sis revealed  an  overall  percentage  RSV  positivity
rate of  18.7%  during  1996—2013.  The  sensitiv-
ity of  the  assays  used  in  various  studies  may  be
variable  [38].  Jansen  et  al.  [39]  described  a signif-
icant  efﬁciency  of  nasal  swabs  compared  to  throat
swabs  for  RSV  detection  among  different  sample
types. The  sample  types  collected  from  patients  in
l
v
i
[s  review.  Immunoﬂuorescence  (IF),  reverse  transcription
orbent  assay  (ELISA),  immunochromatography  (IMC).
tudies  included  in  our  survey  included  nasopha-
yngeal swabs  (42.8%),  nasopharyngeal  aspirate
14.3%),  both  nasopharyngeal  swabs  and  aspirates
9.5%),  throat  swabs  (19%),  serum  (4.8%),  plasma
4.8%); 4.8%  of  studies  did  not  provide  this  infor-
ation  (Table  1) [13,24,25,27,28,40—55]. Conse-
uently,  proper  sampling  and  standard  techniques
re highly  recommended  to  avoid  underestimating
SV-associated  disease  burden  due  to  low-quality
pecimens [31].
Several  reasons  could  explain  the  controversy
egarding RSV  infection  rates.  First,  the  low  sen-
itivity  of  conventional  virus  detection  tests  such
s immunochromatography,  ELISA,  and  immunoﬂuo-
escence assays,  were  exploited  in  several  studies
Table  1; Fig.  3).  These  methods  are  12—50%  less
ensitive  than  PCR-based  methods  [3,38].  Second,
SV might  have  been  cleared  prior  to  sampling  and
elayed sampling  may  lead  to  underestimation  of
he true  viral  infection  rate.  Third,  viral  RNA  may
ave degraded  during  storage  in  hospital  freezers.
inally,  differences  in  study  design,  sample  types,
ospitalization  period,  and  patient  age  might  inﬂu-
nce study  outcomes.  However,  these  discrepancies
ight also  reﬂect  real  regional  and  temporal  differ-
nces.
Besides  epidemiological  characteristics,  sig-
iﬁcant genetic  variation  in  circulating  strains
ay involve  different  pathogenicity  and  virulence
mong patients  with  RSV  infections.  Several  pub-
ications  have  recently  documented  that  novel
ariants may  have  enhanced  clinical  severity  with
ncreased  replication  in  the  lower  respiratory  tract
34,36].  However,  our  ﬁndings  do  not  support  these
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Rrevalence  of  human  respiratory  syncytial  virus  circ
bservations.  Emerging  RSV  variants  with  a selec-
ive advantage  due  to  increased  genetic  diversity
ay confer  low  cross-protection  by  pre-existing
ntibodies to  RSV  strains  previously  circulating
n Iran.  Multiple  genotypes  co-circulated  during
007—2013. The  co-circulation  of  multiple  geno-
ypes  in  some  regions  of  Iran  might  be  associated
ith the  outbreak  of  RSV  among  children  with  fever
nd respiratory  symptoms  in  the  epidemic  season
Fig.  2).
Because  there  are  few  studies  on  the  molecular
pidemiology  of  RSV  in  Iran,  a  larger  population-
ased study  is  required  to  further  delineate  the
ssociation  of  clinical  severity  of  infection  with
irus genotype  in  different  areas.  Better  under-
tanding of  the  molecular  epidemiology  of  RSV  will
rove instrumental  in  developing  efﬁcient  vaccines
nd antiviral  pharmacotherapy  [8,9,35].  There
ere several  limitations  in  our  study,  including:  (1)
SV viral  load  was  not  measured  by  quantitative
CR; viral  load  may  have  been  associated  with  co-
nfection  or  disease  severity.  (2)  Most  studies  were
onducted  in  a  single  hospital  or  city;  however,
atterns of  RSV  genotype  frequency  and  distribu-
ion may  vary  with  location.  (3)  Not  all  regions
n Iran  were  studied  or  surveyed  for  RSV  geno-
ypes, and  additional  RSV  genotypes  are  possible.
4) No  data  were  available  on  the  timing  of  dis-
ase onset.  Despite  these  limitations,  our  study  is
he ﬁrst  and  complete  review  on  RSV  epidemiol-
gy in  Iran  covering  research  over  the  last  17  years
13,24,25,27,28,40—55].
Although  deaths  associated  with  RSV  have  been
are in  the  last  two  decades  [3], and  no  reported
ethal RSV  infections  were  reported  in  Iran,  the
SV mortality  rate  may  not  be  zero.  Clinicians
hould consider  that  children  suffering  from  com-
lex  chronic  conditions  [6]  and  genetic  disorders  [7]
re  signiﬁcantly  more  prone  to  death  from  severe
SV  infections.  Therefore,  more  comprehensive
opulation-based  studies  on  pediatric  infectious
iseases are  required  to  determine  the  risk  factors
f severe  RSV  infections  in  Iran.
In conclusion,  this  review  highlights  the  neces-
ity of  a  standard  molecular  surveillance  program
n Iran.  Future  investigations  of  different  areas  of
ran, particularly  regions  with  a  paucity  of  data,
re needed  in  order  to  determine  RSV  prevalence
nd genotype  distribution  nationwide.  Improving
SV surveillance  would  allow  timely  understanding
f the  epidemiological,  clinical,  and  pathologi-
al characteristics  of  novel  RSV  genotypes.  Since
igh-risk  populations  are  at  increased  risk  of  RSV
nfection  and  there  is no  data  about  passive  immu-
ization  against  RSV  in  Iran,  this  information  will
ssist policy  makers  in  determining  which  regionsing  in  Iran  133
nd  sub-populations  will  most  beneﬁt  from  RSV  pro-
hylaxis and  treatment.
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